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Introduction: Patients with end-stage renal disease (ESRDPos) usually have multiple comorbidities and are
predisposed to acute organ failure and in-hospital mortality. We assessed the effect of ESRD on the poorly
understood long-term mortality risk after a first-ever mechanical ventilation (1-MV) for acute respiratory failure.
Methods: The data source was Taiwan’s National Health Insurance (NHI) Research Database. All patients given
a 1-MV between 1999 and 2008 from one million randomly selected NHI beneficiaries were identified (n = 38,659).
Patients with or without ESRD (ESRDNeg) after a 1-MV between 1999 and 2008 were retrospectively compared and
followed from the index admission date to death or the end of 2011. ESRDPos patients (n = 1185; mean age: 65.9 years;
men: 51.5 %) were individually matched to ESRDNeg patients (ratio: 1:8) using a propensity score method. The primary
outcome was death after a 1-MV. The effect of ESRD on the risk of death after MV was assessed. A Cox proportional
hazard regression model was used to assess how ESRD affected the mortality risk after a 1-MV.
Results: The baseline characteristics of the two cohorts were balanced, but the incidence of mortality was higher in
ESRDPos patients than in ESRDNeg patients (342.30 versus 179.67 per 1000 person-years; P <0.001; covariate-adjusted
hazard ratio: 1.43; 95 % confidence interval: 1.31–1.51). For patients who survived until discharge, ESRD was not
associated with long-term (>4 years) mortality.
Conclusions: ESRD increased the mortality risk after a 1-MV, but long-term survival seemed similar.Introduction
End-stage renal disease (ESRD) is becoming more com-
mon worldwide, especially in Taiwan. Since 2000, the
incidence and prevalence of ESRD have increased [1].
According to the United States Renal Data System,
Taiwan had the highest incidence (418 per million popula-
tion) and prevalence (2226 cases per million population)
of patients on chronic dialysis between 2000 and 2007 [2].
From 2006 to 2010, the number of patients on chronic
dialysis increased from 52,081 to 65,883 (+26.5 %) [3, 4].
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ical illnesses and have a higher mortality than do those
without ESRD (ESRDNeg) [5–11]. However, whether ESRD
per se increases the risk of short-term and long-term mor-
tality after critical illnesses remains controversial [12, 13].
For example, several small cohort studies report that crit-
ically ill patients with ESRD have a higher risk of short-
term mortality than do those without ESRD [8, 14, 15],
and preexisting chronic kidney disease (CKD) indeed has
a marked effect on the development of acute renal failure,
30-day, and 1-year mortality in critically ill patients who
require mechanical ventilation (MV) [16]. Others, how-
ever, have found different results [7, 13]. One large cohort
study showed that critically ill ESRDPos patients had a
similar 1-year mortality rate to those without kidney dys-
function after age, illness severity, and admission type had
been adjusted for [13]. Presumably, the observed differ-
ence in mortality in other studies is largely because ofs distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of acute illnesses rather than because of ESRD [7, 13].
Given these conflicting results, additional research on
longer-term outcomes of these patients is needed.
MV is a life-support measure for patients with acute
respiratory failure (ARF), who have a high rate of in-
hospital mortality (up to 35 %) [17]. When ESRDPos
patients undergo MV, there is a high rate of weaning
failure and mortality [18, 19]. Moreover, when MV is
prolonged, the outcomes for these patients become even
worse, with 1-year mortality as high as 60 % [20]. How-
ever, whether ESRD predicts a worse long-term outcome
in patients who undergo MV is not known.
Studies on critically ill ESRDPos patients focus pri-
marily on those admitted to the intensive care unit
(ICU) [6, 11]. However, not all patients with critical
illnesses are admitted to the ICU [21, 22]. Therefore,
these studies usually have a selection bias. Moreover,
ordering an invasive MV is usually a major critical
decision for life-support measures in ESRDPos pa-
tients, whether or not they are admitted to the ICU.
Information on the effects of ESRD on patients who
undergo MV, instead of those admitted to the ICU,
would be more relevant for patients. Therefore, we
investigated the long-term outcomes of ESRDPos pa-
tients who underwent their first-ever MV (1-MV).
Methods
Data source
The data used in this study are from the National Health
Insurance Research Database (NHIRD) established by
Taiwan’s National Health Research Institute (NHRI) to
improve medical research. Taiwan’s NHI program, insti-
tuted in March 1995, provides coverage for more than
99 % of the country’s legal residents; therefore, the
NHIRD offers detailed healthcare services information
on clinical visits for each insured beneficiary, using
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnostic and pro-
cedure codes [23]. In the present study, data used came
from the Longitudinal Health Insurance Database 2000
(LHID2000) [24], a sub-dataset of the NHI program,
which contains all claims data, from 1996 to 2011, of
one million NHI beneficiaries (about 4.34 % of the total
population) who were randomly selected from the year
2000 Registry of Beneficiaries of the NHIRD. There are
no significant differences in gender distribution between
beneficiaries in the LHID2000 and the NHIRD. The
study was done according to the Declaration of Helsinki
and was approved by the Institutional Review Board
(IRB) at Chi Mei Medical Center (10308-E01). The IRB
waived the need for informed consent from the enrolled
participants because the data used in this study consists
of nationwide, de-identified, secondary data released tothe public for research purposes. This waiver does not
adversely affect the rights and welfare of the enrollees.
Patient selection and definition
We enrolled all inpatients with a 1-MV for ARF dur-
ing their first hospitalization between 1999 and 2008
(n = 38,659). ESRDPos patients (ICD-9-CM code 585)
were detected using the NHI’s catastrophic illness
certification records, which included those who had
undergone regular dialysis for at least 3 months.
Those who were diagnosed with ESRD after a 1-MV
were excluded (n = 1,013). The enrolled ESRDPos patients
(n = 1,331) were then, using propensity score matching
and the greedy matching algorithm (without replacement),
individually matched to ESRDNeg controls in a 1:8 ra-
tio. The propensity score, i.e., the probability of being
ESRDPos, was estimated using a logistic regression
model conditional on the covariates age, sex, length
of ICU stay, length of hospital stay, duration of MV,
department to which admitted, number of organ fail-
ures (other than respiratory and renal systems) [25],
and individual comorbidities: diabetes mellitus (DM),
hypertension (HTN), coronary artery disease (CAD),
cirrhosis, chronic obstructive pulmonary disease (COPD),
cancer, stroke, and congestive heart failure (CHF)
(Additional file 1). Propensity score matching was
used to reduce selection bias because it can bundle
many confounding covariates that might be present in
an observational study with this number of variables.
The characteristics of the two groups were balanced
after the propensity score matching (Table 1).
Endpoint
The primary endpoint (outcome) of the study was death
after MV. Patients were followed from the index admis-
sion date to death or to the end of 2011. The secondary
endpoint was to identify the risk factors for all-cause
mortality after a 1-MV. We hypothesized that mortality
is higher in ESRDPos patients than in ESRDNeg patients
who require MV. The demographic and clinical charac-
teristics of age; sex; length of hospital stay, length of
ICU stay, and duration of MV; department to which ad-
mitted; number of organ failures; and comorbidities
were used to estimate the mortality risk.
Statistical analysis
Differences in baseline characteristics between groups
were evaluated using Pearson’s χ2 test for categorical
variables and Student’s t test for continuous variables.
The incidence rate (IR) of death was calculated as cases
per person-year. The overall and subgroup-specific rela-
tive mortality risks between the two groups were esti-
mated using the incidence rate ratio (IRR) with a 95 %
confidence interval (CI) using the Poisson assumption.
Table 1 Baseline characteristics of the study participants before and after propensity score matching
Before propensity score matching After propensity score matching
Variables ESRDPos ESRDNeg P ESRDPos ESRDNeg P
Total 1331 (3.54) 36,315 (96.46) 1185 (11.11) 9480 (88.89)
Age, years (mean ± SD) 65.02 ± 12.97 62.84 ± 20.65 <0.0001 65.90 ± 13.47 65.48 ± 14.99 0.3005
Age group, years <0.0001 0.8569
<50 159 (11.95) 8454 (23.28) 152 (12.83) 1264 (13.33)
50–64 422 (31.71) 7079 (19.49) 339 (28.61) 2731 (28.81)
≧65 750 (56.35) 20,782 (57.23) 694 (58.57) 5485 (57.86)
Sex <0.0001 0.2491
Female 689 (51.77) 13,407 (36.92) 575 (48.52) 4432 (46.75)
Male 642 (48.23) 22,908 (63.08) 610 (51.48) 5048 (53.25)
Comorbidity
Diabetes 703 (52.82) 9779 (26.93) <0.0001 568 (47.93) 4379 (46.19) 0.2573
Hypertension 903 (67.84) 15,755 (43.38) <0.0001 757 (63.88) 5954 (62.81) 0.4697
CAD 458 (34.41) 8173 (22.51) <0.0001 377 (31.81) 2948 (31.10) 0.6153
Liver cirrhosis 137 (10.29) 2954 (8.13) 0.0048 120 (10.13) 1025 (10.81) 0.4722
COPD 175 (13.15) 8715 (24.00) <0.0001 175 (14.77) 1394 (14.70) 0.9538
Cancer 184 (13.82) 7912 (21.79) <0.0001 183 (15.44) 1475 (15.56) 0.9172
Stroke 368 (27.65) 9952 (27.40) 0.8448 343 (28.95) 2711 (28.60) 0.8027
CHF 279 (20.96) 5024 (13.83) <0.0001 215 (18.14) 1699 (17.92) 0.8514
Department to which admitted <0.0001 0.6634
Surgery 325 (24.42) 14,358 (39.54) 324 (27.34) 2649 (27.94)
Medical 1006 (75.58) 21,957 (60.46) 861 (72.66) 6831 (72.06)
Number of organ failures (other than
lungs and kidneys)
<0.0001 0.8884
0 960 (72.13) 28,900 (79.58) 867 (73.16) 6979 (73.62)
1 346 (26.00) 6779 (18.67) 294 (24.81) 2298 (24.24)
≧2 25 (1.88) 636 (1.75) 24 (2.03) 203 (2.14)
Ventilator duration (days) (continuous) 11.69 ± 25.34 18.15 ± 84.99 <0.0001 11.57 ± 25.23 11.93 ± 29.57 0.6494
ICU days, mean ± SD 10.25 ± 16.48 9.75 ± 17.18 0.2839 9.93 ± 15.32 10.07 ± 17.18 0.7883
Hospital days, mean ± SD 24.06 ± 28.14 25.28 ± 54.04 0.1391 23.92 ± 28.21 22.89 ± 32.11 0.2444
Data are number (percentages) unless otherwise specified
ESRD end stage renal disease, ESRDPos patients with ESRD, ESRDNeg patients without ESRD, CAD coronary artery disease, COPD chronic obstructive airway disease,
CHF congestive heart disease, ICU intensive care unit
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mined using the Kaplan-Meier method, and a log-rank
test was used to compare the difference between the two
survival curves. The effect of ESRD on the mortality risk
after MV was assessed using a Cox proportional hazards
regression model. Covariates included in the Cox model
were those used in the propensity score matching
(mentioned in the “Patient selection and definition”
subsection above). The proportional hazard assump-
tion was verified using plots of natural log trans-
formed (ln) (survival function) versus ln (time). The
data are mean ± standard deviation or number (per-
centages). Significance was set at P <0.05. SAS 9.3.1for Windows (SAS Institute, Cary, NC, USA) was
used for all analyses.
Results
The initial survey included 37,646 patients. After match-
ing, 10,665 patients with a 1-MV (ESRDPos: 1185 and
ESRDNeg: 9480) were selected. Before propensity score
matching, the ESRDPos group contained more patients
who were older, female, and had comorbid DM, HTN,
CAD, cirrhosis, and CHF, and contained fewer patients
who had COPD and cancer, a higher prevalence of one
or more organ failures, and fewer days on MV than did
ESRDNeg patients (Table 1). In addition, about 12.17 %
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36,315) of the ESRDNeg patients had undergone MV out-
side the ICU (data not shown). After propensity score
matching, with the correction of all the above variables,
1185 (90.39 %) of the 1331 ESRDPos patients were
matched to 9480 ESRDNeg controls (Table 1). The mor-
tality rate of ESRDPos patients was nearly twice as high
as that of ESRDNeg patients (IRR = 1.92) (Table 2). The
risk difference in mortality between the two groups was
significant across all subgroups with the exception of
those with liver cirrhosis, cancer, and multiple organTable 2 The overall and subgroup-specific incidence rates (IR) and i
matched ESRDNeg controls
Variables ESRDPos patients ESRD
Total (n) Death (n) IR (per 1000 person-years) Total
All 1185 898 342.30 9480
Age group, years
<50 152 90 175.34 1264
50–64 339 241 261.52 2731
≧65 694 567 477.04 5485
Sex
Male 610 474 388.34 5048
Female 575 424 302.25 4432
Comorbidity
Diabetes 568 447 411.98 4379
Hypertension 757 570 336.70 5954
CAD 377 293 386.34 2948
Liver cirrhosis 120 101 481.91 1025
COPD 175 153 602.27 1394
Cancer 183 138 339.96 1475
Stroke 343 278 463.19 2711
CHF 215 161 338.72 1699
Department to which admitted
Surgery 324 225 257.56 2649
Medical 861 673 384.60 6831
Number of organ failures (other than lungs and kidneys)
0 867 633 290.32 6979
1 294 245 589.45 2298
≧2 24 20 728.53 203
Follow-up
0–6 month 1185 717 2497.50 9480
6–12 months 468 44 197.37 5035
1–2 years 424 46 115.34 4772
2–4 years 378 52 76.36 4451
4–6 years 292 22 45.21 3616
> = 6 years 196 17 31.08 2537
ESRD end stage renal disease, ESRDPos with ESRD, ESRDNeg without ESRD, IRR inciden
disease, COPD chronic obstructive airway disease, CHF congestive heart diseasefailure. The highest risk difference was for patients ad-
mitted to the Surgery Department (IRR = 2.95), and the
lowest was for patients with CHF (IRR = 1.35). In follow-
ups within 4 years, ESRDPos patients had a higher mor-
tality rate (IRR, 0–6 months: 1.59; 6–12 months: 1.84;
1–2 years: 1.65 and 2–4 years: 1.69). After 4 years of
follow-up, however, there was no significant difference
in mortality rates between ESRDPos and ESRDNeg pa-
tients. The 30-day, 6-month, and 1-, 2-, 5-, and 10-year
survival rate differences in the ESRDPos and ESRDNeg
groups from the beginning are listed in Additional file 2.ncidence rate ratios (IRR) of death between ESRDPos patients and
Neg controls IRR (95 % CI) P
(n) Death (n) IR (per 1000 person-years)
5806 179.67 1.92 (1.79–2.07) <0.0001
509 80.90 2.17 (1.73–2.71) <0.0001
1481 142.16 1.84 (1.61–2.11) <0.0001
3816 244.53 1.95 (1.79–2.13) <0.0001
3102 179.79 2.16 (1.96–2.38) <0.0001
2704 179.64 1.68 (1.52–1.86) <0.0001
2946 224.98 1.83 (1.66–2.02) <0.0001
3764 193.81 1.74 (1.59–1.90) <0.0001
1830 181.80 2.13 (1.88–2.40) <0.0001
839 449.78 1.07 (0.87–1.32) 0.5123
960 219.92 2.74 (2.31–3.25) <0.0001
1068 294.69 1.15 (0.97–1.38) 0.1142
1852 236.90 1.96 (1.72–2.22) <0.0001
1179 251.31 1.35 (1.14–1.59) 0.0004
1133 87.26 2.95 (2.56–3.41) <0.0001
4673 241.73 1.59(1.47–1.72) <0.0001
3812 136.93 2.12 (1.95–2.31) <0.0001
1818 430.62 1.37 (1.20–1.56) <0.0001
176 691.46 1.05 (0.66–1.67) 0.8249
4445 1571.80 1.59 (1.47–1.72) <0.0001
263 107.515 1.84 (1.33–2.53) 0.0002
321 69.83 1.65 (1.21–2.25) 0.0015
374 45.28 1.69 (1.26–2.25) 0.0004
186 30.25 1.49 (0.96–2.32) 0.0747
217 27.01 1.15 (0.70–1.89) 0.5570
ce rate ratio, CI confidence interval, IR incidence rate, CAD coronary artery
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decline in mortality early on, and a parallel course there-
after, which suggests that although the starting point is
lower, the trajectory has not changed (Fig. 1). After 4
years, the survival curves seem to be almost parallel,
which might indicate that ESRD increases short-term
but not long-term mortality. Patients who were older,
had more organ failures, and had been admitted to the
Surgery Department had a significantly higher mortality
(Fig. 2a–c), but there was no significant difference in the
survival rate between males and females (Fig. 2d).
ESRDPos patients had a lower survival rate than did
ESRDNeg patients (hazard ratio [HR] 1.43; 95 % CI:
1.33–1.54). In addition to ESRD, some important factors
predicting mortality for patients after a 1-MV included
older age (50–64 years old: HR = 1.50; ≥65 years old:
HR = 2.03: compared with 0–50 years old), being female
(HR = 0.94), admitted to a surgery department (0.64),
more organ failures (1: HR = 1.85; ≥2: HR = 2.46:
compared with 0), DM (HR = 1.18), liver cirrhosis
(HR = 1.61), cancer (1.49), stroke (1.26), and CHF
(1.17) (Table 3). The HR of death in ESRDPos pa-
tients treated with MV is shown in Additional file 3.
Discussion
We found that after age, severity of illness, comorbidi-
ties, and department to which admitted had been
adjusted for, ESRD after a 1-MV was associated with a
higher risk for mortality (HR = 1.43), regardless of
whether the patient had been admitted to the ICU. We
also found that about 9.85 % (3707/37,646) of ESRDPos
1-MV patients had never been admitted to the ICU
(data not shown), which is consistent with other reportsFig. 1 Kaplan-Meier survival curves of ESRDPos patients and ESRDNeg contro[21, 22]. The present study appears to be the first to
describe long-term outcomes of ESRDPos patients with a
1-MV and to include patients not admitted to the ICU.
Our findings are compatible with most other studies on
ESRDPos patients admitted to the ICU. One study of
276,731 adults admitted to the ICU reported that after
the patients had been discharged from the ICU, in-
hospital mortality rates were much higher in ESRDPos
patients than in ESRDNeg patients (45.3 % versus 31.2 %;
P <0.001) [9].
Go et al. also showed that ESRDPos patients have a
relative risk for all-cause mortality 5.9 times greater than
do patients with healthy renal function [26]. Another
study reported that ESRDPos patients had higher rates of
ICU and in-hospital mortality than did matched pairs of
patients (23.1 % versus 15.1 %, and 31.2 % versus 19.1 %,
P <0.05) [10]. Other studies have reported that critically
ill patients on chronic dialysis are estimated to have the
following mortality rates: in-hospital: 14 % to 56 %, 30-
day: 32 % to 41 %, and 90-day: 42 % to 44.6 % [6], and
that longer-term mortality rates might be as high as 38
% (6 months) and 48 % (12 months) [27]. There are few
studies on the long-term outcomes of ESRDPos patients
after a 1-MV, except for one on 47 patients, which re-
ported an overall cumulative proportional in-hospital
survival rate of only 17 %, a 1-year rate of 40 %, and
a 3-year rate of 25 % [18]. Liao et al. also said that
ESRDPos patients had a significantly higher mortality
rate than did ESRDNeg patients (76.7 % versus 28.8 %)
1 year after traumatic brain injury [28]. Those studies were
exclusively on patients admitted to the ICU, however.
In contrast, others have found different results. A large
population-based cohort study of nonspecific critically illls. ESRD end stage renal disease
Fig. 2 Kaplan-Meier survival curves of different groups: (a) age; (b) number of organ failures; (c) departments to which patients were admitted;
(d) sex
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function is associated with an increased risk for long-
term death, with the exception of ESRDPos patients, who
had outcomes similar to those of patients with no kidney
dysfunction [13]. Strijack et al. [7] said that the
unadjusted in-hospital mortality rate was higher for
ESRDPos patients (16 % versus 11 %), but that this differ-
ence did not persist after an adjustment for baseline illness
severity, and that the higher mortality rate was due to co-
morbidity but not to ESRD itself. Moreover, Chapman
et al. [29] reported that ESRDPos patients who were alive
after they had been discharged from the ICU had a 2-year
survival rate of 56 %, but that the long-term mortality rate
between ESRDPos patients and matched ESRDNeg controls
was similar after excluding patients who had died within a
month of being discharged from the ICU [29]. We
thought that because of different inclusion criteria, critic-
ally ill ESRDPos patients might have different long-term
outcomes because they have different comorbidities.
Despite possible bias, including possible MV patients not
admitted to the ICU, and matching using propensityscores, our study showed that ESRDPos patients with a 1-
MV had a higher IRR of death per 1000 person-years than
did almost all the groups (stratified by age, sex, depart-
ment admitted by, number of organ failures, and comor-
bidities) and a higher covariate-adjusted HR (1.43) than
did ESRDNeg controls. The long-term outcomes and the
long-term mortality rates of those who survived for more
than 4 years after they had been discharged from the hos-
pital were similar between ESRDPos and ESRDNeg patients.
After a Cox proportional hazards analysis, we showed
that the mortality predictors of our patients treated with
MV included ESRD, older age, and being male, findings
consistent with the literature. Other researchers have
reported that ESRD predicted in-hospital or 30-day
mortality in patients with ARF and MV admitted to the
ICU in spite of aggressive treatment [19, 30], and that
for patients with prolonged MV, ESRD also predicted
1-year mortality [20]. Moreover, many studies have re-
ported the effect of age on the mortality of patients
treated with MV [13, 20, 30–34]. For example, a retro-
spective study [34] of 61,113 patients treated with MV
Table 3 Crude and adjusted hazard ratios (HR) of death in all











50–64 1.51 (1.37–1.66) 1.50 (1.36–1.65)
≧65 2.18 (1.99–2.38) 2.03 (1.85–2.23)
Sex
Female 1.00 (0.95–1.05) 0.94 (0.89–0.99)
Male 1.00 1.00
Comorbidity
Diabetes 1.30 (1.24–1.36) 1.18 (1.13–1.25)
Hypertension 1.10 (1.05–1.16) 0.99 (0.94–1.05)
Coronary artery disease 1.00 (0.95–1.06) 0.93 (0.88–1.01)
Liver cirrhosis 1.90 (1.77–2.04) 1.61 (1.50–1.74)
COPD 1.20 (1.12–1.28) 1.01 (0.95–1.08)
Cancer 1.33 (1.24–1.41) 1.49 (1.39–1.59)
Stroke 1.28 (1.21–1.34) 1.26 (1.19–1.33)
CHF 1.24 (1.17–1.32) 1.17 (1.10–1.25)
Department to which admitted
Surgery 0.50 (0.47–0.53) 0.64 (0.60–0.68)
Medical 1.00 1.00
Number of organ failures (other than lungs and kidneys)
0 1.00 1.00
1 2.14 (2.03–2.26) 1.85 (1.75–1.95)
≥2 2.79 (2.41–3.23) 2.46 (2.12–2.86)
Ventilator duration (days) (continuous) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
ICU stay (days) (continuous) 1.00 (1.00–1.00) 1.00 (1.00–1.01)
Hospital stay (days) (continuous) 0.99 (0.99–1.00) 1.00 (0.99–1.00)
HR hazard ratio, CI confidence interval, ESRD end-stage renal disease, COPD
chronic obstructive airway disease, CHF congestive heart disease, ICU intensive
care unit
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increased mortality rate included being >80 years old,
and two recent studies also reported that older age
was a consistent hazard [30, 32]. Esteban et al. [31],
too, said that older age (40–70 years: HR = 1.60 and
>70 years: HR = 2.11, compared with <40 years) was
associated with a higher ICU mortality rate in 5183
patients treated with MV, which is in line with our
finding.
In addition, the influence of sex on mortality rates in
patients treated with MV is inconsistent. One study re-
ported that women had a greater risk for in-hospitalmortality [35], but another reported no such association
[30]. In contrast, two large studies showed that being
male predicted higher in-hospital mortality in patients
treated with MV [36, 37]. Our study showed no signifi-
cant differences in survival between the sexes, but the
difference was significant after bias had been adjusted
for. Differences in inclusion criteria, race, population-
based cohorts, and geographic distribution make it diffi-
cult to generalize the effect of sex on critically ill
patients.
Our study is also consistent with the literature, which
shows that patients admitted to medical rather than sur-
gical departments have more organ failures, and that co-
morbidities (e.g., DM, liver cirrhosis, cancer, stroke, and
CHF) predicted worse outcomes. Manzano et al. found
that a medical department admission was a significant
predictor of mortality in patients requiring MV [38].
Other studies report that multiple organ failure is inde-
pendently associated with mortality in patients with MV
[30, 34, 39]. Similarly, the comorbidities of DM, CHF,
stroke, liver cirrhosis, and cancer have been reported as
independent predictors of short-term and long-term
mortality in patients with MV [30, 32, 34, 38, 40, 41],
which is consistent with our findings.
We also found that ESRDPos patients with MV were
older, more often admitted to medical departments; and
more often had comorbid DM, HTN, CAD, liver cirrho-
sis, and CHF than did ESRDNeg patients before match-
ing, although these factors could also be mortality
contributors after matching. This was consistent with
other studies [9, 10, 26]. In general, patients on long-
term dialysis admitted to the ICU tend to have higher
illness severity scores and multiple comorbidities, and to
need more medical resources than does the general
population [1].
Strengths and limitations
Our study has some strengths. First, it is a large
population-based analysis of the effect of ESRD on pa-
tients given a 1-MV, which includes patients not admit-
ted to the ICU; this differentiates the present study from
others. Second, the nationwide study design largely re-
duced the effect of referral bias, which is often seen in
critical care studies.
Our study also has some limitations. First, all diagno-
ses, including comorbidities, relied on the claims data
and ICD-9-CM diagnosis codes, which might lead to
disease misclassification. Second, the NHIRD does not
differentiate the stages of CKD in ESRDNeg patients.
Third, we were unable to take into account the illness
severity scores of ESRDPos patients with MV because the
data were unavailable; thus, we included the number of
organ failures as a proxy for severity. Fourth, as in all
observational studies, our study might contain some
Chen et al. Critical Care  (2015) 19:354 Page 8 of 9residual confounding; thus, it cannot show causality but
only association between risk factors and mortality. Fifth,
we excluded 146 ESRDPos patients (>10 %) because we
were unable to match them with ESRDNeg patients; this
might contribute bias to our conclusions. Finally, not all
patients were admitted to the ICU, which might have af-
fected our evaluations of outcomes.Conclusions
Regardless of whether a patient is admitted to the ICU,
being ESRDPos significantly increases the risk of death
within 4 years after a 1-MV. After 4 years, however, sur-
vival rates are not significantly different. In addition to
ESRD, older age, being male, being admitted by a med-
ical department, multiple organ failure, and a history of
comorbidities (DM, liver cirrhosis, cancer, stroke, and
CHF) are associated with a higher mortality rate after a
1-MV. Physicians should keep these high-risk groups in
mind and explain the prognosis to patients’ families
when treating critical patients undergoing a 1-MV.Key messages
 ESRD-positive patients who underwent their first-ever
mechanical ventilation were older, more often female,
admitted to a medical department, had comorbid
diabetes mellitus, hypertension, coronary artery
disease, liver cirrhosis, and congestive heart failure
than did ESRD-negative control patients before
propensity score matching.
 After matching, the mortality rate of ESRD-positive
patients was nearly twice as high as that of
ESRD-negative patients.
 ESRD-positive patients had a significantly higher
risk of death within 4 years after a first-ever
mechanical ventilation, whether or not they
were admitted to the intensive care unit.
 After 4 years of follow-up, however, there was no
significant difference in mortality rates between
ESRD-positive and ESRD-negative patients.
 In addition to ESRD, older age, being male, being
admitted by a medical department, multiple organ
failure, and a history of comorbid diabetes mellitus,
liver cirrhosis, cancer, stroke, and congestive heart
failure are associated with a higher mortality rate
after a first-ever mechanical ventilation.Additional files
Additional file 1: ICD-9CM codes for comorbidities. (DOCX 13 kb)
Additional file 2: The 30-day, 6-month, and 1-, 2-, 5-, and 10-year
survival rate differences in the ESRDPos and ESRDNeg groups from
the beginning. (DOCX 17 kb)Additional file 3: Crude and adjusted hazard ratios (HR) of death in
ESRDPos patients treated with ventilation (derived from Cox
proportional hazard regression models). (DOCX 16 kb)
Abbreviations
1-MV: first-ever mechanical ventilation; ARF: acute respiratory failure;
CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence
interval; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary
disease; DM: diabetes mellitus; ESRD: end-stage renal disease; ESRDNeg: controls
without ESRD; ESRDPos: patients with ESRD; HR: hazard ratio; HTN: hypertension;
ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical
Modification; ICU: intensive care unit; IR: incidence rate; IRB: Institutional Review
Board; IRR: incidence rate ratio; LHID2000: Longitudinal Health Insurance
Database 2000; MV: mechanical ventilation; NHIRD: National Health Insurance
Research Database; NHRI: National Health Research Institute.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CMC contributed to the study design, helped collect data, and helped draft
the manuscript. SFW contributed to the study design, helped do the
statistical analysis, and revised the manuscript. CCL and KCC contributed to
the study design and revised the manuscript. HNS contributed to the study
design, helped collect data, helped do the statistical analysis, and revised the
manuscript. WLL helped collect data and revise the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
We thank the staff of the Taiwan Bureau of National Health Insurance,
Bureau of Health Promotion, and Department of Health. This research was
funded by grant number CMFHR10446 from Chi-Mei Medical Center.
Author details
1Department of Recreation and Health-Care Management, Chia Nan
University of Pharmacy and Science, No.60, Sec. 1, Erren Road., Rende District,
Tainan 71710, Taiwan. 2Department of Hospital and Health Care
Administration, Chia Nan University of Pharmacy and Science, Tainan,
Taiwan. 3Southern Taiwan University of Science and Technology, No. 1,
Nan-Tai Street, Yungkang District, Tainan 710, Taiwan. 4Department of
Intensive Care Medicine, Chi Mei Medical Center, 901 Chung Hwa Road,
Yungkang District, Tainan 710, Taiwan. 5Department of Internal Medicine, Chi
Mei Medical Center, 901 Chung Hwa Road, Yungkang District, Tainan 710,
Taiwan. 6Department of Healthcare Administration and Medical Informatics,
Kaohsiung Medical University, Kaohsiung, Taiwan. 7Department of Intensive
Care Medicine, Chi Mei Medical Center, Liouying District, 201, Taikang,
Taikang Village, Liouying District, Tainan 736, Taiwan. 8Department of Safety,
Health and Environment, Chung Hwa University of Medical Technology, 89,
Wenhua 1st Street, Rende District, Tainan 717, Taiwan. 9Department of Public
Health, College of Medicine, National Cheng Kung University, 1, University
Road, Tainan 701, Taiwan.
Received: 15 May 2015 Accepted: 18 September 2015
References
1. Yang WC, Hwang SJ. Taiwan Society of N. Incidence, prevalence and
mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to
2001: the impact of national health insurance. Nephrol Dial Transplant.
2008;23:3977–82.
2. U.S. Renal Data System. USRDS 2008 Annual Data Report: atlas of end-stage
renal disease in the United States. Bethesda, MD: National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
3. The Report of National Health Insurance, 2007 [in Chinese]. Bureau of
National Health Insurance (BNHI), Department of Health, Republic of
China (Taiwan); 2007. http://www.nhi.gov.tw/Resource/webdata/
Attach_8965_2_%E9%87%8D%E5%A4%A7%E5%82%B7%E7%97%85%E9%
A0%98%E8%AD%89%E6%95%B8%E8%A1%A818-%E9%99%84%E4%BB%
B68.pdf. Asscessed in 14 July 2015.
Chen et al. Critical Care  (2015) 19:354 Page 9 of 94. The Report of National Health Insurance, 2011 [in Chinese]. Bureau of
National Health Insurance (BNHI), Department of Health, Republic of China
(Taiwan); 2011. http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&
menu_id=661&WD_ID=685&webdata_id=3627. Accessed 14 July 2015.
5. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US
Renal Data System 2013 Annual Data Report. Am J Kidney Dis. 2014;63:A7.
6. Chan M, Ostermann M. Outcomes of chronic hemodialysis patients in the
intensive care unit. Crit Care Res Pract. 2013;2013:715807.
7. Strijack B, Mojica J, Sood M, Komenda P, Bueti J, Reslerova M, et al.
Outcomes of chronic dialysis patients admitted to the intensive care unit.
J Am Soc Nephrol. 2009;20:2441–7.
8. Uchino S, Morimatsu H, Bellomo R, Silvester W, Cole L. End-stage renal
failure patients requiring renal replacement therapy in the intensive care
unit: incidence, clinical features, and outcome. Blood Purif. 2003;21:170–5.
9. Hutchison CA, Crowe AV, Stevens PE, Harrison DA, Lipkin GW. Case mix,
outcome and activity for patients admitted to intensive care units requiring
chronic renal dialysis: a secondary analysis of the ICNARC Case Mix
Programme Database. Crit Care. 2007;11:R50.
10. Apel M, Maia VP, Zeidan M, Schinkoethe C, Wolf G, Reinhart K, et al.
End-stage renal disease and outcome in a surgical intensive care unit.
Crit Care. 2013;17:R298.
11. Arulkumaran N, Annear NM, Singer M. Patients with end-stage renal disease
admitted to the intensive care unit: systematic review. Br J Anaesth.
2013;110:13–20.
12. Bell M, Granath F, Schon S, Lofberg E, SWING, Ekbom A, et al. End-stage
renal disease patients on renal replacement therapy in the intensive care
unit: short- and long-term outcome. Crit Care Med. 2008;36:2773–8.
13. Bagshaw SM, Mortis G, Doig CJ, Godinez-Luna T, Fick GH, Laupland KB.
One-year mortality in critically ill patients by severity of kidney dysfunction:
a population-based assessment. Am J Kidney Dis. 2006;48:402–9.
14. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal
failure in the ICU: comparison of the impact of acute renal failure and
end-stage renal disease on ICU outcomes. Kidney Int. 2002;62:986–96.
15. Manhes G, Heng AE, Aublet-Cuvelier B, Gazuy N, Deteix P, Souweine B.
Clinical features and outcome of chronic dialysis patients admitted to an
intensive care unit. Nephrol Dial Transplant. 2005;20:1127–33.
16. Lebiedz P, Knickel L, Engelbertz C, Luders F, Gebauer K, Berdel WE, et al.
Impact of preexisting chronic kidney disease on acute and long-term
outcome of critically ill patients on a medical intensive care unit. J Nephrol.
2014;27:73–80.
17. Esteban A, Frutos-Vivar F, Muriel A, Ferguson ND, Penuelas O, Abraira V,
et al. Evolution of mortality over time in patients receiving mechanical
ventilation. Am J Respir Crit Care Med. 2013;188:220–30.
18. Chen SC, Shu KH, Chen CH, Wu MY, Yu TM, Chuang YW, et al. Outcome
study of patients on maintenance hemodialysis complicated with acute
respiratory failure: 1-year data from a medical center in central Taiwan. Acta
Nephrol. 2010;24:33–41.
19. Juneja D, Prabhu MV, Gopal PB, Mohan S, Sridhar G, Nayak KS. Outcome of
patients with end stage renal disease admitted to an intensive care unit in
India. Ren Fail. 2010;32:69–73.
20. Leroy G, Devos P, Lambiotte F, Thevenin D, Leroy O. One-year mortality in
patients requiring prolonged mechanical ventilation: multicenter evaluation
of the ProVent score. Crit Care. 2014;18:R155.
21. Cely CM, Rojas JT, Maldonado DA, Schein RM, Quartin AA. Use of intensive
care, mechanical ventilation, both, or neither by patients with acute lung
injury. Crit Care Med. 2010;38:1126–34.
22. Esquinas AM, Dikmen Y. Mechanical ventilation outside intensive care unit.
A growing demand in a vulnerable population. Are there possible
solutions? J Crit Care. 2013;28:876–7.
23. National Health Insurance Administration http://www.nhi.gov.tw/English/
Index.aspx?menu=13&menu_id=486&WD_ID=486. Accessed in 14 July 2015.
24. Center for Biomedical Resources of National Health Research Institutes
http://nhird.nhri.org.tw/en/Data_Subsets.html. Dec, 2014.
25. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan
from 1997 through 2006. Chest. 2010;138:298–304.
26. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease
and the risks of death, cardiovascular events, and hospitalization. N Engl J
Med. 2004;351:1296–305.
27. Sood MM, Miller L, Komenda P, Reslerova M, Bueti J, Santhianathan C, et al.
Long-term outcomes of end-stage renal disease patients admitted to the
ICU. Nephrol Dial Transplant. 2011;26:2965–70.28. Liao JC, Ho CH, Liang FW, Wang JJ, Lin KC, Chio CC, et al. One-year
mortality associations in hemodialysis patients after traumatic
brain injury–an eight-year population-based study. PLoS One.
2014;9:e93956.
29. Chapman RJ, Templeton M, Ashworth S, Broomhead R, McLean A, Brett SJ.
Long-term survival of chronic dialysis patients following survival from an
episode of multiple-organ failure. Crit Care. 2009;13:R65.
30. Azevedo LC, Park M, Salluh JI, Rea-Neto A, Souza-Dantas VC, Varaschin P,
et al. Clinical outcomes of patients requiring ventilatory support in Brazilian
intensive care units: a multicenter, prospective, cohort study. Crit Care.
2013;17:R63.
31. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, et al.
Characteristics and outcomes in adult patients receiving mechanical
ventilation: a 28-day international study. JAMA. 2002;287:345–55.
32. Franca SA, Toufen CJ, Hovnanian AL, Albuquerque AL, Borges ER, Pizzo VR,
et al. The epidemiology of acute respiratory failure in hospitalized patients:
a Brazilian prospective cohort study. J Crit Care. 2011;26:330. e1-8.
33. Carson SS, Kahn JM, Hough CL, Seeley EJ, White DB, Douglas IS, et al. A
multicenter mortality prediction model for patients receiving prolonged
mechanical ventilation. Crit Care Med. 2012;40:1171–6.
34. Behrendt CE. Acute respiratory failure in the United States: incidence and
31-day survival. Chest. 2000;118:1100–5.
35. Kollef MH, O'Brien JD, Silver P. The impact of gender on outcome from
mechanical ventilation. Chest. 1997;111:434–41.
36. Mahmood K, Eldeirawi K, Wahidi MM. Association of gender with outcomes
in critically ill patients. Crit Care. 2012;16:R92.
37. Chen CJ, Shi HY, Lee KT, Huang TY. In-hospital mortality prediction in
patients receiving mechanical ventilation in Taiwan. Am J Crit Care.
2013;22:506–13.
38. Manzano F, Perez-Perez AM, Martinez-Ruiz S, Garrido-Colmenero C, Roldan
D, Jimenez-Quintana Mdel M, et al. Hospital-acquired pressure ulcers and
risk of hospital mortality in intensive care patients on mechanical
ventilation. J Eval Clin Pract. 2014;20:362–8.
39. Jeong BH, Suh GY, An JY, Park MS, Lee JH, Lee MG, et al. Clinical
demographics and outcomes in mechanically ventilated patients in Korean
intensive care units. J Korean Med Sci. 2014;29:864–70.
40. Golestanian E, Liou JI, Smith MA. Long-term survival in older critically ill
patients with acute ischemic stroke. Crit Care Med. 2009;37:3107–13.
41. Levesque E, Saliba F, Ichai P, Samuel D. Outcome of patients with cirrhosis
requiring mechanical ventilation in ICU. J Hepatol. 2014;60:570–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
